CADTH launches call for patient input on AMX0035

October 27, 2021 – Make your voice heard! The Canadian Agency for Drugs and Technology in Health (CADTH) has posted a call for patient input on AMX0035. ALS Canada will be preparing a submission reflecting the perspectives of the ALS community and we are inviting you to contribute. In early November, you will have the opportunity to participate in a survey where you can share your perspectives, experiences and expectations for the therapy.

Your input will help to ensure that issues of importance to patients are considered by decision-makers at CADTH, who ultimately recommend whether public drug plans should cover the drug if it is approved by Health Canada. A concurrent Health Canada and CADTH review is just one step of many in aligning the drug access processes to the urgent needs of the ALS community.

At this time, Health Canada has not yet finished its review of AMX0035, so a decision about its approval is still to come. You can learn more about how drugs become accessible in Canada by visiting our blog post on this topic.

To be notified when the survey launches, you can sign up to have ALS Canada’s blog posts pushed to your inbox.